2023
Gurjar, R., Dickinson, L., Carr, D., Stohr, W., Bonora, S., Owen, A., . . . Boffito, M. (2022). Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study. PHARMACOGENOMICS JOURNAL. doi:10.1038/s41397-022-00293-5DOI: 10.1038/s41397-022-00293-5
2022
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199DOI: 10.1093/cid/ciac199
2021
Dickinson, L., Walimbwa, S., Singh, Y., Kaboggoza, J., Kintu, K., Sihlangu, M., . . . Orrell, C. (2021). Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. CLINICAL INFECTIOUS DISEASES, 73(5), E1200-E1207. doi:10.1093/cid/ciaa1861DOI: 10.1093/cid/ciaa1861
Herrera, C., Lwanga, J., Lee, M., Mantori, S., Amara, A., Else, L., . . . Fox, J. (2021). Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2129-2136. doi:10.1093/jac/dkab136DOI: 10.1093/jac/dkab136
De Francesco, D., Wang, X., Dickinson, L., Underwood, J., Bagkeris, E., Babalis, D. S., . . . Boffito, M. (2021). Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. PLOS ONE, 16(7). doi:10.1371/journal.pone.0253861DOI: 10.1371/journal.pone.0253861
2020
Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F. A., . . . POPPY Study. (2020). Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV.. AIDS, 34(5), 790-793. doi:10.1097/QAD.0000000000002479DOI: 10.1097/QAD.0000000000002479
Dickinson, L., Gurjar, R., Stoehr, W., Bonora, S., Owen, A., D'Avolio, A., . . . Boffito, M. (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 628-639. doi:10.1093/jac/dkz479DOI: 10.1093/jac/dkz479
Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F. A., . . . POPPY Study. (2020). Plasma NRTI concentration and their associations with liver and renal parameters in people living with HIV.. AIDS. doi:10.1097/QAD.0000000000002479DOI: 10.1097/QAD.0000000000002479
2019
Duwal, S., Seeler, D., Dickinson, L., Khoo, S., & von Kleist, M. (2019). The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. FRONTIERS IN PHARMACOLOGY, 10. doi:10.3389/fphar2019.00199DOI: 10.3389/fphar2019.00199
Duwal, S., Seeler, D., Dickinson, L., Khoo, S., & von Kleist, M. (2019). The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis.. Frontiers in pharmacology, 10, 199. doi:10.3389/fphar.2019.00199DOI: 10.3389/fphar.2019.00199
Gini, J., Olagunju, A., Dickinson, L., Waitt, C., Neary, M., Else, L. J., . . . Khoo, S. (2019). Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. PHARMACOGENOMICS, 20(4), 217-224. doi:10.2217/pgs-2018-0111DOI: 10.2217/pgs-2018-0111
Duwal, S., Dickinson, L., Khoo, S., & von Kleist, M. (2019). Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis.. PLoS computational biology, 15(1), e1006740. doi:10.1371/journal.pcbi.1006740DOI: 10.1371/journal.pcbi.1006740
Olagunju, A., Anweh, D., Okafor, O., Dickinson, L., Richman, D., Owen, A., & Adejuyigbe, E. (2019). Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study. doi:10.12688/wellcomeopenres.15072.1DOI: 10.12688/wellcomeopenres.15072.1
2018
Duwal, S., Dickinson, L., Khoo, S., & von Kleist, M. (2018). Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. PLOS COMPUTATIONAL BIOLOGY, 14(6). doi:10.1371/journal.pcbi.1006155DOI: 10.1371/journal.pcbi.1006155
Plasma NRTI concentrations and renal function in people with HIV (Conference Paper)
Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI concentrations and renal function in people with HIV. In HIV MEDICINE Vol. 19 (pp. S16-S17). Retrieved from https://www.webofscience.com/
Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV (Conference Paper)
Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from https://www.webofscience.com/
2017
de Knegt, G. J., Dickinson, L., Pertinez, H., Evangelopoulos, D., McHugh, T. D., Bakker-Woudenberg, I. A. J. M., . . . de Steenwinkel, J. E. M. (2017). Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. TUBERCULOSIS, 105, 113-118. doi:10.1016/j.tube.2017.05.002DOI: 10.1016/j.tube.2017.05.002
A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days (Journal article)
Wootton, D. G., Dickinson, L., Pertinez, H., Court, J., Eneje, O., Keogan, L., . . . Diggle, P. J. (2017). A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days. European Respiratory Journal, 49(6). doi:10.1183/13993003.02170-2016DOI: 10.1183/13993003.02170-2016
2016
Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.. Journal of acquired immune deficiency syndromes (1999), 73(3), 252-257. doi:10.1097/qai.0000000000001108DOI: 10.1097/qai.0000000000001108
Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 73(3), 252-257. Retrieved from https://www.webofscience.com/
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5DOI: 10.1007/s40262-015-0360-5
Siccardi, M., Dickinson, L., & Owen, A. (n.d.). Validation of computational approaches for antiretroviral dose optimization. Antimicrobial Agents and Chemotherapy, 60, 3838-3839. doi:10.1128/AAC.00094-16DOI: 10.1128/AAC.00094-16
Siccardi, M., Dickinson, L., & Owen, A. (2016). Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). Retrieved from http://gateway.webofknowledge.com/
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1041-1045. doi:10.1093/jac/dkv439DOI: 10.1093/jac/dkv439
Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity (Conference Paper)
Bracchi, M., Pagani, N., Clarke, A., Adams, T., Waters, L., Bolton, M., . . . Nelson, M. (2016). Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/
Dickinson, L., Bracchi, M., Elliot, E., Else, L., Khoo, S., Back, D., . . . Boffito, M. (2016). Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/
2015
Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15DOI: 10.1128/AAC.01441-15
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study (Journal article)
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.
The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age (Journal article)
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV CLINICAL TRIALS, 16(1), 39-42. doi:10.1179/1528433614Z.0000000006DOI: 10.1179/1528433614Z.0000000006
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. (Journal article)
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.. HIV clinical trials, 16(1), 39-42.
2014
Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi (Journal article)
Dickinson, L., Chaponda, M., Carr, D. F., van Oosterhout, J. J., Kumwenda, J., Lalloo, D. G., . . . Khoo, S. H. (2014). Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(2), 706-712. doi:10.1128/AAC.02069-13DOI: 10.1128/AAC.02069-13
Raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age: a Phase 1 pharmacokinetic study (Journal article)
Vera, J., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2014). Raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age: a Phase 1 pharmacokinetic study. HIV MEDICINE, 15, 116. Retrieved from https://www.webofscience.com/
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.. Journal of the International AIDS Society, 17(4 Suppl 3), 19586. doi:10.7448/ias.17.4.19586DOI: 10.7448/ias.17.4.19586
2013
Population Pharmacokinetics of Twice Daily Zidovudine in HIV-Infected Children and an assessment of ZDV exposure following WHO dosing guidelines (Conference Paper)
Dickinson, L., Fillekes, Q., Cressey, T. R., Chokephaibulkit, K., Davies, G. R., Musiime, V., . . . Walker, S. (2013). Population Pharmacokinetics of Twice Daily Zidovudine in HIV-Infected Children and an assessment of ZDV exposure following WHO dosing guidelines. In Reviews in Antiviral Therapy and Infectious Diseases Vol. 3 (pp. 45). Retrieved from http://regist2.virology-education.com/abstractbook/2013_3.pdf
Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies (Journal article)
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231DOI: 10.1097/QAI.0b013e3182737231
2012
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Boffito, M., . . . Back, D. (2012). Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose. Journal of the International AIDS Society, 15(4).
Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095DOI: 10.3851/IMP2095
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval (Journal article)
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrobial Agents and Chemotherapy, 56(9), 4583-4585.
Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations (Journal article)
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 816-824. doi:10.1128/AAC.05186-11DOI: 10.1128/AAC.05186-11
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. (Journal article)
Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. (Journal article)
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.. Antiviral therapy, 17(1), 19-24. doi:10.3851/imp1910DOI: 10.3851/imp1910
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.
Predicting ritonavir-boosted saquinavir exposure in HIV-infected patients aged 2-15 years using adult data as prior information (Conference Paper)
Dickinson, L., Levi, M., Davies, G., Khoo, S., Pozniak, A., Boffito, M., & Back, D. (2012). Predicting ritonavir-boosted saquinavir exposure in HIV-infected patients aged 2-15 years using adult data as prior information. In 13th International Workshop on Clinical Pharmacology of HIV Therapy Vol. -.
2011
Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. (Journal article)
Ashby, J., Garvey, L., Erlwein, O. W., Lamba, H., Weston, R., Legg, K., . . . Winston, A. (2011). Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.. The Journal of antimicrobial chemotherapy, 66(6), 1340-1345. doi:10.1093/jac/dkr093DOI: 10.1093/jac/dkr093
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10DOI: 10.1128/AAC.00887-10
Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology (Poster)
Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy (Journal article)
Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25(5), 722-725. doi:10.1097/QAD.0b013e3283445700DOI: 10.1097/QAD.0b013e3283445700
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. (Journal article)
Else, L., Lyons, F., O'shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.. AIDS, 25(5), 722-725.
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy (Journal article)
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV MEDICINE, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.xDOI: 10.1111/j.1468-1293.2010.00865.x
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy (Journal article)
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.xDOI: 10.1111/j.1468-1293.2010.00865.x
Population Pharmacokinetic Modelling of Plasma and Intracellular Once Daily Ritonavir-Boosted Darunavir in HIV-Infected Patients (Abstract O_12)) (Journal article)
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Winston, A., . . . Back, D. (2011). Population Pharmacokinetic Modelling of Plasma and Intracellular Once Daily Ritonavir-Boosted Darunavir in HIV-Infected Patients (Abstract O_12)). Reviews in Antiviral Therapy and Infectious Diseases, 3, 13. Retrieved from http://regist2.virology-education.com/abstractbook/2011_3.pdf
2010
Grapefruit-Drug Interactions (Journal article)
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-Drug Interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000DOI: 10.2165/11585250-000000000-00000
Grapefruit-drug interactions. (Journal article)
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-drug interactions.. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000DOI: 10.2165/11585250-000000000-00000
Pharmacokinetic evaluation of etravirine (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion on Drug Metabolism & Toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811DOI: 10.1517/17425255.2010.535811
Pharmacokinetic evaluation of etravirine. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine.. Expert opinion on drug metabolism & toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811DOI: 10.1517/17425255.2010.535811
Dickinson, L., Chaponda, M., Carr, D., van Oosterhout, J. J., Kumwenda, J., Lalloo, D. G., . . . Khoo, S. H. (2010). Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. In Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection Vol. 13 (pp. 181). Glasgow, UK: Journal of the International AIDS Society. doi:10.1186/1758-2652-13-S4-P181DOI: 10.1186/1758-2652-13-S4-P181
Population pharmacokinetic modelling of once‐daily ritonavir‐boosted darunavir in HIV‐infected patients (Conference Paper)
Dickinson, L., Jackson, A. G. A., Garvey, L. J., Watson, V., Khoo, S. H., Winston, A., . . . Back, D. J. (2010). Population pharmacokinetic modelling of once‐daily ritonavir‐boosted darunavir in HIV‐infected patients. In Journal of the International AIDS Society Vol. 13. Wiley. doi:10.1186/1758-2652-13-s4-p184DOI: 10.1186/1758-2652-13-s4-p184
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. (Journal article)
Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.. Antiviral therapy, 15(2), 213-218. doi:10.3851/imp1517DOI: 10.3851/imp1517
Grapefruit juice drug interactions (Journal article)
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit juice drug interactions. Drugs, 70(18), 2373-2407.
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189.
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017DOI: 10.1016/j.antiviral.2009.07.017
Pharmacokinetics and drug–drug interactions of antiretrovirals: An update (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug–drug interactions of antiretrovirals: An update. Antiviral Research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017DOI: 10.1016/j.antiviral.2009.07.017
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. (Journal article)
Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . DART Trial Team. (2010). Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.. Antimicrobial agents and chemotherapy, 54(7), 2965-2973. doi:10.1128/aac.01198-09DOI: 10.1128/aac.01198-09
Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults (Journal article)
Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . on behalf of the DART trial team. (2010). Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Antimicrob Agents Chemother, 54(7), 2965-2973.
Sequential population pharmacokinetic modelling of lopinavir and ritonavir: Investigation of different dosing strategies (Conference Paper)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2010). Sequential population pharmacokinetic modelling of lopinavir and ritonavir: Investigation of different dosing strategies. In 11th International Workshop on Clinical Pharmacology of HIV Therapy (pp. P63). Sorrento: Virology Education.
Tenofovir and efavirenz plasma concentrations in HIV-infected patients aged 50 years or over (Conference Paper)
Yau, S., Dickinson, L., Back, D., Ward, B., Hughes, A., Sonecha, S., . . . Boffito, M. (2010). Tenofovir and efavirenz plasma concentrations in HIV-infected patients aged 50 years or over. In 2nd Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASSH) (pp. P21). Manchester: British HIV Association.
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. (Journal article)
Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.. Antiviral therapy, 15(2), 213-218.
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy (Conference Paper)
Lambert, J., Else, L., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2010). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. In 2nd Joint Conference of the British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASSH) (pp. P12). Manchester: British HIV Association.
2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers (Journal article)
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102DOI: 10.1093/jac/dkp102
An exploratory analysis to determine the feasibility of raltegravir population pharmacokinetics in HIV-infected patients and healthy volunteers (Conference Paper)
Dickinson, L., Back, D., Watson, V., Davies, G., Aarons, L., Khoo, S., . . . Boffito, M. (2009). An exploratory analysis to determine the feasibility of raltegravir population pharmacokinetics in HIV-infected patients and healthy volunteers. In 10th International Workshop on Clinical Pharmacology of HIV Therapy (pp. P10). Amsterdam: Virology Education.
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2009). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, (in pr.
Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients (Conference Paper)
Chaponda, M., Dickinson, L., Davies, G., van Oosterhout, J. J., Kumwenda, J., Zijlstra, E., . . . Khoo, S. (2009). Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients. In 10th International Workshop on Clinical Pharmacology of HIV Therapy (pp. P60). Amsterdam: Virology Education.
Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients (Conference Paper)
Chaponda, M., Dickinson, L., Davies, G., van Oosterhout, J. J., Kumwenda, J., Zijlstra, E., . . . Khoo, S. (2009). Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients. In 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (pp. WePeB259). Cape Town: International AIDS Society.
Pharmacokinetics (PK) of plasma abacavir (ABC) and its intracellular (IC) anabolite carbovir-triphosphate (CBV-TP) in the absence and in the presence of darunavir/ritonavir (DRV/r) or raltegravir (RAL) in HIV-infected subjects (Conference Paper)
Jackson, A., Gedela, K., Dickinson, L., Back, D., Taylor, J., Abongomera, G., . . . Boffito, M. (2009). Pharmacokinetics (PK) of plasma abacavir (ABC) and its intracellular (IC) anabolite carbovir-triphosphate (CBV-TP) in the absence and in the presence of darunavir/ritonavir (DRV/r) or raltegravir (RAL) in HIV-infected subjects. In 12th European AIDS Conference (EACS) (pp. PE4.3/2). Cologne: European AIDS Clinical Society.
Population pharmacokinetics of nevirapine in HIV-infected adults (Conference Paper)
Schipani, A., Wakeham, K., Ggayi, A., Kamali, A., Lalloo, D. G., Youle, M., . . . Back, D. (2009). Population pharmacokinetics of nevirapine in HIV-infected adults. In 15th British HIV Association (BHIVA) Meeting (pp. P139). Liverpool: British HIV Association.
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected and healthy individuals (Conference Paper)
Dickinson, L., Aarons, L., Back, D., Waters, L., Else, L., Khoo, S., . . . Boffito, M. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected and healthy individuals. In 15th British HIV Association (BHIVA) Meeting (pp. P140). Liverpool: British HIV Association.
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers (Journal article)
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother, 63(6), 1233-1243.
The effects of a novel nucleoside-sparing antiretroviral regimen on the pharmacokinetic profile of once-daily ritonavir-boosted darunavir in HIV-1 infected subjects (Conference Paper)
Garvey, L., Latch, N., Erlwein, O. W., Mohammed, P., Mackie, N. E., Walsh, J., . . . Winston, A. (2009). The effects of a novel nucleoside-sparing antiretroviral regimen on the pharmacokinetic profile of once-daily ritonavir-boosted darunavir in HIV-1 infected subjects. In 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (pp. LBPEB08). Cape Town: International AIDS Society.
2008
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals (Journal article)
Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1344-1355. doi:10.1093/jac/dkn399DOI: 10.1093/jac/dkn399
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing (Journal article)
Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (n.d.). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62(1), 161-167. doi:10.1093/jac/dkn187DOI: 10.1093/jac/dkn187
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.. Therapeutic drug monitoring, 30(3), 306-313.
Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313. doi:10.1097/FTD.0b013e318177209eDOI: 10.1097/FTD.0b013e318177209e
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. (Journal article)
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.. Clinical pharmacology and therapeutics, 83(6), 867-872. doi:10.1038/sj.clpt.6100375DOI: 10.1038/sj.clpt.6100375
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. (Journal article)
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.. Clinical pharmacology and therapeutics, 83(6), 867-872.
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, 3(3), 296-305.
Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs (Conference Paper)
Chaikan, A., Chierakul, N., Saguenwong, N., Chuchuttaworn, C., Owen, A., Dickinson, L., . . . Davies, G. R. (2008). Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs. In Journal of the International AIDS Society Vol. 11 (pp. P237). Wiley. doi:10.1186/1758-2652-11-s1-p237DOI: 10.1186/1758-2652-11-s1-p237
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit, 30(3), 306-313.
Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study (Conference Paper)
Dickinson, L., Boffito, M., Else, L. J., Moyle, G. J., Khoo, S. H., Pozniak, A., & Aarons, L. (2008). Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study. In Journal of the International AIDS Society Vol. 11 (pp. P241). Wiley. doi:10.1186/1758-2652-11-s1-p241DOI: 10.1186/1758-2652-11-s1-p241
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing (Journal article)
Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. J Antimicrob Chemother, 62(1), 161-167.
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects (Journal article)
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther, 83(6), 867-872.
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected individuals and healthy volunteers (Conference Paper)
Dickinson, L., Aarons, L., Back, D., Waters, L., Else, L., Khoo, S., . . . Boffito, M. (2008). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected individuals and healthy volunteers. In British Pharmacological Society (BPS) 2008 Winter Meeting (pp. P069). Brighton: Wiley-Blackwell.
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals (Journal article)
Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother, 62(6), 1344-1355.
2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367. doi:10.1097/ftd.0b013e3180683b25DOI: 10.1097/ftd.0b013e3180683b25
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367.
A simple pharmacokinetic analysis to assess the forgiveness for late dosing of boosted saquinavir regimens (Conference Paper)
Dickinson, L., Back, D., Khoo, S., Shutz, M., & Boffito, M. (2007). A simple pharmacokinetic analysis to assess the forgiveness for late dosing of boosted saquinavir regimens. In 8th International Workshop on Clinical Pharmacology of HIV Infection (pp. 14). Budapest: Virology Education.
Population pharmacokinetics of boosted saquinavir regimens in HIV-infected individuals (Conference Paper)
Dickinson, L., Boffito, M., Back, D., Khoo, S., Pozniak, A., Byakika, P., . . . Aarons, L. (2007). Population pharmacokinetics of boosted saquinavir regimens in HIV-infected individuals. In British Pharmacological Society (BPS) 2007 Winter Meeting (pp. CP021). Brighton: Wiley-Blackwell.
Prediction of once daily boosted protease inhibitor pharmacokinetic profiles based on twice daily concentration data (Conference Paper)
Dickinson, L., Back, D., Khoo, S., Boffito, M., Pozniak, A., Davis, J., & Aarons, L. (2007). Prediction of once daily boosted protease inhibitor pharmacokinetic profiles based on twice daily concentration data. In 11th European AIDS Conference (EACS) (pp. P4.1/02). Madrid: European AIDS Clinical Society.
Total and unbound lopinavir pharmacokinetics during pregnancy and at delivery in HIV-infected women (Conference Paper)
Else, L., Dickinson, L., Bell, C., Douglas, M., Back, D., Khoo, S., & Taylor, G. (2007). Total and unbound lopinavir pharmacokinetics during pregnancy and at delivery in HIV-infected women. In 8th International Workshop on Clinical Pharmacology of HIV Infection (pp. 10). Budapest: Virology Education.
2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. (Journal article)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2006). Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.. AIDS research and human retroviruses, 22(8), 749-756.
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. (Journal article)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2006). Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.. AIDS research and human retroviruses, 22(8), 749-756. doi:10.1089/aid.2006.22.749DOI: 10.1089/aid.2006.22.749
Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz concentrations (Conference Paper)
Else, L., Dickinson, L., Schellenberger, M., Khoo, S., & Back, D. (2006). Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz concentrations. In 8th International Congress on Drug Therapy in HIV Infection (pp. P272). Glasgow: Journal of the International AIDS Society.
Factors Influencing Inter-Individual Variability in Pharmacokinetics of Antiretrovirals in HIV-Infected Patients (Thesis / Dissertation)
Dickinson, L. (2006). Factors Influencing Inter-Individual Variability in Pharmacokinetics of Antiretrovirals in HIV-Infected Patients. (PhD Thesis, University of Liverpool).
Intra-patient variability and comparison of saquinavir/ritonavir Ctrough concentrations between HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500mg film-coated tablets (1000/100mg twice daily) (Conference Paper)
Dickinson, L., Back, D., Winston, A., Khoo, S., & Boffito, M. (2006). Intra-patient variability and comparison of saquinavir/ritonavir Ctrough concentrations between HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500mg film-coated tablets (1000/100mg twice daily). In 7th International Workshop on Clinical Pharmacology of HIV Therapy (pp. 60). Lisbon: Virology Education.
Strategies to Aid Pharmacokinetic Studies Of Antiretrovirals In Developing Countries (Conference Paper)
Dickinson, L., Hamdulay, N., Else, L., Khoo, S., & Back, D. (2006). Strategies to Aid Pharmacokinetic Studies Of Antiretrovirals In Developing Countries. In 9th European ISSX Meeting (pp. 92). Manchester: Informa.
Trough concentrations in HIV patients receiving boosted hard-gel capsules (HGC) and 500mg film-coated tablet (FCT) formulations of saquinavir (Conference Paper)
Dickinson, L., Back, D., Winston, A., Khoo, S., & Boffito, M. (2006). Trough concentrations in HIV patients receiving boosted hard-gel capsules (HGC) and 500mg film-coated tablet (FCT) formulations of saquinavir. In 8th International Congress on Drug Therapy in HIV Infection (pp. P271). Glasgow: Journal of the International AIDS Society.
2005
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. (Journal article)
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90.
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. (Journal article)
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90. doi:10.1016/j.jchromb.2005.09.032DOI: 10.1016/j.jchromb.2005.09.032
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. (Journal article)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2005). Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.. The Journal of antimicrobial chemotherapy, 55(4), 542-545. doi:10.1093/jac/dki043DOI: 10.1093/jac/dki043
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily (Journal article)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2005). Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. J Antimicrob Chemother, 55(4), 542-545.
Drug-Drug Interactions (Chapter 28) (Chapter)
Meemken, L., & Dickinson, L. (2005). Drug-Drug Interactions (Chapter 28). In C. Hoffman, J. K. Rockstroch, & B. S. Kamps (Eds.), HIV Medicine 2005 (pp. 693-794). Paris, Cagliari, Wuppertal, Sevilla: Flying Publisher.
Is once-daily dosing of PIs associated with decreased tolerance for missed or late doses? (Conference Paper)
Gibbons, S., Dickinson, L., Boffito, M., Pozniak, A., Back, D., & Khoo, S. (2005). Is once-daily dosing of PIs associated with decreased tolerance for missed or late doses?. In 10th European AIDS Conference (EACS) (pp. PE 4.1/8). Dublin: European AIDS Clinical Society.
Limited sampling strategy analysis to predict AUC of twice-daily boosted saquinavir (1000/100mg bid) (Conference Paper)
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2005). Limited sampling strategy analysis to predict AUC of twice-daily boosted saquinavir (1000/100mg bid). In 10th European AIDS Conference (EACS) (pp. PE4.1/9). Dublin: European AIDS Clinical Society.
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry (Journal article)
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 829((1-2)), 82-90.
The impact of co-infection with Hepatitis C or Hepatitis B on lopinavir pharmacokinetics in patients infected with HIV (Conference Paper)
Dickinson, L., Micheli, V., Meraviglia, P., Tjia, J., Almond, L., Regazzi, M., . . . Cargnel, A. (2005). The impact of co-infection with Hepatitis C or Hepatitis B on lopinavir pharmacokinetics in patients infected with HIV. In 3rd IAS Conference on HIV Pathogenesis and Treatment (pp. WePe3.2C06). Rio de Janeiro: International AIDS Society.
The impact of gender on saquinavir hard-gel/ritonavir (1000/100 mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals (Conference Paper)
Dickinson, L., Back, D., Chandler, B., Owen, A., Khoo, S., Pozniak, A., & Boffito, M. (2005). The impact of gender on saquinavir hard-gel/ritonavir (1000/100 mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. In 6th International Workshop on Clinical Pharmacology of HIV Therapy (pp. 9). Quebec: Virology Education.
2004
Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 37(3), 1376-1384. doi:10.1097/01.qai.0000136060.65716.1aDOI: 10.1097/01.qai.0000136060.65716.1a
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.. Journal of acquired immune deficiency syndromes (1999), 37(3), 1376-1384. doi:10.1097/01.qai.0000136060.65716.1aDOI: 10.1097/01.qai.0000136060.65716.1a
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral therapy, 9(3), 423-429. doi:10.1177/135965350400900315DOI: 10.1177/135965350400900315
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral therapy, 9(3), 423-429.
Atazanavir but not ritonavir impacts the elimination half life of saquinavir hard gel in HIV+ subjects (Conference Paper)
Boffito, M., Moyle, G., Dickinson, L., Back, D., Hill, A., Maitland, D., . . . Pozniak, A. (2004). Atazanavir but not ritonavir impacts the elimination half life of saquinavir hard gel in HIV+ subjects. In Interscience Conference on the Antimicrobial Agents and Chemotherapy (ICAAC) (pp. A-452). Washington: American Society for Microbiology.
Pharmacokinetics of saquinavir hard gel/ritonavir in combination with different doses of atazanavir (ATV) once daily (OD) in HIV+ patients (Conference Paper)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Moyle, G., . . . Pozniak, A. (2004). Pharmacokinetics of saquinavir hard gel/ritonavir in combination with different doses of atazanavir (ATV) once daily (OD) in HIV+ patients. In 7th International Congress on Drug Therapy in HIV Infection (pp. P272). Glasgow: Journal of the International AIDS Society.
Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients (Conference Paper)
Boffito, M., Back, D., Kurowski, M., Dickinson, L., Krule, G., Hill, A., . . . Pozniak, A. (2004). Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients. In 10th Anniversary Conference of the British HIV Association (pp. O1). Cardiff: British HIV Association.
Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients (Conference Paper)
Boffito, M., Back, D., Kurowski, M., Dickinson, L., Krule, G., Hill, A., . . . Pozniak, A. (2004). Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients. In 5th International Workshop on Clinical Pharmacology of HIV Therapy (pp. 17). Rome: Virology Education.
Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability (Conference Paper)
Boffito, M., Back, D., Dickinson, L., Hill, A., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability. In 10th Anniversary Conference of the British HIV Association (pp. P76). Cardiff: British HIV Association.
Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability (Conference Paper)
Boffito, M., Back, D., Dickinson, L., Hill, A., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability. In 5th International Workshop on Clinical Pharmacology of HIV Therapy (pp. 65). Rome: Virology Education.
Simultaneous administration of saquinavir hard gel and ritonavir is required for optimal SQV absorption (Conference Paper)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2004). Simultaneous administration of saquinavir hard gel and ritonavir is required for optimal SQV absorption. In 44th Interscience Conference on the Antimicrobial Agents and Chemotherapy (ICAAC) (pp. A-453). Washington: American Society for Microbiology.
Steady state pharmacokinetics of saquinavir hard gel/fosamprenavir 1000/700 mg plus 100 mg and 200 mg ritonavir BID in HIV+ patients (Conference Paper)
Boffito, M., Dickinson, L., Hill, A., Nelson, M., Moyle, G., Higgs, C., . . . Pozniak, A. (2004). Steady state pharmacokinetics of saquinavir hard gel/fosamprenavir 1000/700 mg plus 100 mg and 200 mg ritonavir BID in HIV+ patients. In 11th Conference on Retroviruses and Opportunistic Infections (CROI) (pp. 608). San Francisco: Foundation for Retrovirology and Human Health.
The pharmacokinetics (PK) of saquinavir and ritonavir in Ugandan patients receiving ritonavir boosted saquinavir hard gel and soft gel (Conference Paper)
Coakely, P., Merry, C., Kityo, C., Ryan, M., Dickinson, L., Gibbons, S., . . . Mugyenyi, P. (2004). The pharmacokinetics (PK) of saquinavir and ritonavir in Ugandan patients receiving ritonavir boosted saquinavir hard gel and soft gel. In 7th International Congress on Drug Therapy in HIV Infection (pp. P277). Glasgow: Journal of the International AIDS Society.
Therapeutic drug monitoring of atazanavir in routine clinical settings in the UK (Conference Paper)
Gibbons, S., Robinson, L., Dickinson, L., Tjia, J., Robertson, A., Stainsby-Tron, M., . . . Khoo, S. (2004). Therapeutic drug monitoring of atazanavir in routine clinical settings in the UK. In 7th International Congress on Drug Therapy in HIV Infection (pp. P274). Glasgow: Journal of the International AIDS Society.
2003
Factors influencing nevirapine plasma concentrations (Conference Paper)
Gibbons, S. E., Almond, L., Reynolds, H., Dickinson, L., Robinson, L., Khoo, S. H., . . . Back, D. J. (2003). Factors influencing nevirapine plasma concentrations. In 9th Annual Conference of the British HIV Association (pp. P3). Manchester: British HIV Association.
Pharmacokinetics of saquinavir/ritonavir once daily in HIV+ subjects: comparison with standard BD regimens (Conference Paper)
Boffito, M., Dickinson, L., Hill, A., Nelson, M., Moyle, G., Higgs, C., . . . Pozniak, A. (2003). Pharmacokinetics of saquinavir/ritonavir once daily in HIV+ subjects: comparison with standard BD regimens. In 9th European AIDS Conference (EACS) (pp. F2/3). Warsaw: European AIDS Clinical Society.
Saquinavir/ritonavir pharmacokinetics in HIV+ subjects: 1000/100 mg BD vs. 1600/100 and 2000/100 mg once daily (Conference Paper)
Boffito, M., Dickinson, L., Hill, A., Higgs, C., Fletcher, C., Johnson, C., . . . Pozniak, A. (2003). Saquinavir/ritonavir pharmacokinetics in HIV+ subjects: 1000/100 mg BD vs. 1600/100 and 2000/100 mg once daily. In 43rd Interscience Conference on the Antimicrobial Agents and Chemotherapy (pp. A-1612). Chicago: American Society of Microbiology.
